{"groups":[{"description":"Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"FG000","title":"Dasatinib 100 mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"FG001","title":"Dasatinib 140 mg QD"},{"description":"Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"FG002","title":"Dasatinib 50 mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"FG003","title":"Dasatinib 70 mg BID"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"}],"type":"Randomized, never treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"167"},{"groupId":"FG001","numSubjects":"167"},{"groupId":"FG002","numSubjects":"168"},{"groupId":"FG003","numSubjects":"168"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"166"},{"groupId":"FG001","numSubjects":"163"},{"groupId":"FG002","numSubjects":"166"},{"groupId":"FG003","numSubjects":"167"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Randomized to Treatment"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"not reported when site closed"},{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"8"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"42"},{"groupId":"FG002","numSubjects":"29"},{"groupId":"FG003","numSubjects":"27"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"5"}],"type":"Investigator Request"},{"reasons":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"47"},{"groupId":"FG002","numSubjects":"57"},{"groupId":"FG003","numSubjects":"60"}],"type":"non-specified"},{"reasons":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"45"},{"groupId":"FG002","numSubjects":"45"},{"groupId":"FG003","numSubjects":"51"}],"type":"Study Drug Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"19"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"16"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"comment":"Randomized to 50 mg BID but received 100 mg QD.","groupId":"FG000","numSubjects":"165"},{"groupId":"FG001","numSubjects":"163"},{"groupId":"FG002","numSubjects":"167"},{"groupId":"FG003","numSubjects":"167"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"comment":"Randomized to 100 mg QD but received 50 mg BID.","groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"165"},{"groupId":"FG001","numSubjects":"163"},{"groupId":"FG002","numSubjects":"167"},{"groupId":"FG003","numSubjects":"167"}],"type":"NOT COMPLETED"}],"title":"As Treated at Study Closure"}],"preAssignmentDetails":"724 participants were enrolled, 670 were randomized, and 662 were treated with study drug. Reasons for non-randomization: 38 no longer met criteria, 8 other reasons, 7 withdrew consent, and 1 death.","recruitmentDetails":"Study initiated July 2005 and completed July 2014."}